GENMAB ASDK 1 news, videos and press releases - Page 3
For more news please use our advanced search feature.
GENMAB ASDK 1 - More news...
GENMAB ASDK 1 - More news...
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
- Passing of Genmab A/S’ Annual General Meeting
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
- Transactions in connection with share buy-back program
- Notice to Convene the Annual General Meeting of Genmab A/S
- Genmab Files Annual Report with the U.S. Securities and Exchange Commission
- Genmab Announces Initiation of Share Buy-Back Program
- Genmab Publishes 2023 Annual Report
- Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
- Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
- TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
- Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
- Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Genmab to Hold 2023 R&D Update and ASH Data Review Meeting
- New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
